drugset / Trial / NCT01223209
A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
NaSingle-groupOpen-label
Summary
This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour. GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001. LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-12
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUXOTEMITIDE | Peptide | 0.25 mg/ml | Other |
| Subject | RUXOTEMITIDE | Peptide | 2 mg/ml | Other |
| Background | TERTOMOTIDE | Vaccine | 0.1 mg | Other |
| Background | TERTOMOTIDE | Vaccine | 0.56 mg | Other |